SIRPant Immunotherapeutics

SIRPant technology employs an Adoptive Cell Therapy (ACT) approach to elicit tumor-specific T-cells. The approach results in a polyclonal immune response against multiple tumor antigens. The therapy has broad applicability for unmet needs in the treatment of solid tumors.